Compromise or not? A case report of successful treatment of pembrolizumab‐induced hepatitis in a patient with non‐small cell lung cancer with low‐dose methylprednisolone and bicyclol

Pembrolizumab, an anti‐programmed cell death protein 1 (PD‐1) antibody, has been shown to improve survival in patients with non‐small cell lung cancer (NSCLC) with high expression of programmed death‐ligand 1 (PD‐L1). Corticosteroids are the mainstay for most high‐grade immune‐related adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan'e, Zhang, Jie, Yin, Zhongnan, Zhu, Xiang, Xue, Lixiang, Cao, Baoshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327908/
https://www.ncbi.nlm.nih.gov/pubmed/32379397
http://dx.doi.org/10.1111/1759-7714.13463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327908/
https://www.ncbi.nlm.nih.gov/pubmed/32379397
http://dx.doi.org/10.1111/1759-7714.13463

Ejemplares similares